Gilead Sciences Amends Officer and Director Filings

TL;DR

Gilead Sciences 8-K/A filed: amendments to officer/director changes and compensation. No new financials.

AI Summary

Gilead Sciences, Inc. filed an 8-K/A on December 13, 2024, to amend a previous filing from July 17, 2024. The amendment pertains to the departure of certain officers and the election of directors, as well as compensatory arrangements for specific officers. The filing does not appear to involve any new financial statements or exhibits.

Why It Matters

This filing clarifies changes in Gilead's corporate governance and executive compensation structure, which can impact investor confidence and strategic direction.

Risk Assessment

Risk Level: low — The filing is an amendment to previous disclosures regarding corporate governance and executive compensation, not a new material event.

Key Players & Entities

• GILEAD SCIENCES, INC. (company) — Registrant
• Delaware (jurisdiction) — State of Incorporation
• July 17, 2024 (date) — Date of earliest event reported in original filing
• December 13, 2024 (date) — Filing date of the 8-K/A

FAQ

From the Filing

0001104659-24-128088.txt : 20241213 0001104659-24-128088.hdr.sgml : 20241213 20241212173827 ACCESSION NUMBER: 0001104659-24-128088 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240717 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241213 DATE AS OF CHANGE: 20241212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GILEAD SCIENCES, INC. CENTRAL INDEX KEY: 0000882095 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 943047598 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19731 FILM NUMBER: 241546143 BUSINESS ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 6505743000 MAIL ADDRESS: STREET 1: 333 LAKESIDE DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: GILEAD SCIENCES INC DATE OF NAME CHANGE: 19930328 8-K/A 1 tm2430889d1_8ka.htm FORM 8-K/A false 0000882095 0000882095 2024-07-17 2024-07-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549       FORM 8-K/A       CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): July 17, 2024       GILEAD SCIENCES, INC. (Exact name of registrant as specified in its charter)   Delaware 0-19731 94-3047598 (State or Other Jurisdiction of Incorporation) (Commission File No.) (IRS Employer Identification No.)   333 Lakeside Drive , Foster City , California (Address of principal executive offices)   94404 (Zip Code)   650 - 574-3000 (Registrant’s Telephone Number, Including Area Code)       Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, par value, $0.001 per share   GILD   The Nasdaq Global Select Market   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ( §240.12b-2 of this chapter).   Emerging growth company ¨   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨             Item 5.02        Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   As previously announced by Gilead Sciences, Inc., a Delaware corporation (the “Company”), Merdad V. Parsey, M.D., Ph.D., the Co